The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Molecular mechanisms of blood vessel growth
Abstract
Time for primary review 12 days. From the earliest stages, the embryo develops in the absence of vascularization, receiving its nutrition by diffusion [1]. In an ordered and sequential manner, however, the embryo rapidly transforms into a highly vascular organism, survival being dependent on a functional, complex network of capillary plexuses and blood vessels. ‘Vasculogenesis’ refers to the initial events in vascular growth in which endothelial cell precursors (angioblasts) migrate to discrete locations, differentiate in situ and assemble into solid endothelial cords, later forming a plexus with endocardial tubes (Fig. 1). The subsequent growth, expansion and remodeling of these primitive vessels into a mature vascular network is referred to as ‘angiogenesis’ (Fig. 1). This process is characterized by a combination of sprouting of new vessels from the sides and ends of pre-existing ones, or by longitudinal division of existing vessels with periendothelial cells (intussusception), either of which may then split and branch into precapillary arterioles and capillaries. Depending on the ultimate fate with respect to the type of vessel (artery, vein, capillary) and vascular bed, activated endothelial cells that are migrating and proliferating to form new vessels, forming anastomotic connections with each other, become variably surrounded by layers of periendothelial cells — pericytes for small vessels and smooth muscle cells for large vessels (‘vascular myogenesis’) (Fig. 1) [2]. During this dynamic period, extracellular matrix produced by mural cells, serves to stabilize the network. Finally, further functional modifications of larger arteries occur during ‘arteriogenesis’ as a thick muscular coat is added, concomitant with acquisition of viscoelastic and vasomotor properties (Fig. 1). Endothelial precursors (angioblasts) in the embryo assemble in a primitive network (vasculogenesis), that expands and remodels (angiogenesis). Smooth muscle cells cover endothelial cells during vascular myogenesis, and stabilize vessels during arteriogenesis. CL, collagen; EL, elastin; Fib, fibrillin. With permission from Ref. [4]. It is clear that for vasculogenesis and angiogenesis to effectively proceed during physiological and pathological conditions, it is essential that a complex array of angiogenic and anti-angiogenic factors, interacting with multiple cells and tissues, be tightly regulated. Although endothelial cells have attracted the most attention, they alone cannot complete the process of vessel growth and development, as peri-endothelial cells and matrix components play essential roles. Innovative gene technologies and advances in animal modeling have enabled research scientists to make major advances in understanding the mechanisms of blood vessel growth. The ultimate therapeutic goals, which are to mitigate against angiogenesis during pathological processes such as inflammation and tumorigenesis, and to enhance angiogenesis to prevent and/or treat ischemic events, have become realizable at the clinical level, and thus caught the imagination and attention of all those involved in health care and research [3,4]. In the past 15–20 years, major breakthroughs have resulted in the emergence of useful paradigms to help explain vasculogenesis and angiogenesis. This review provides an update on some of the basic molecular mechanisms governing how endothelial cells, smooth muscle cells, matrix molecules, and several critical receptors and their ligands, interact with each other to form blood vessels. As will become evident, the rapid growth in our understanding has provided scientists with new and exciting potential options to address the therapeutic goals. However, there are still many aspects of vasculogenesis and angiogenesis that remain challenges to our knowledge. These are being met with remarkable rapidity. Clear evidence of blood vessel development first appears outside of the embryo proper, on the yolk sac, as focal aggregations of mesenchymal cells, known as blood islands, form within the mesoderm adjacent to the extraembyronic endoderm. While the earliest studies suggested that the embryo proper becomes vascularized from branching and growth of extraembyronic blood vessels which in turn are derived from fusion and channeling of blood islands, intraembryonic origins of a vascular network were recognized as early as 1900 when it was determined that cells from isolated embryos were able to give rise to blood vessels. It was at this time that the term angioblast, referring to the cells from which all endothelial cells arise, was described. It was also during this early period that the presence of the hemangioblast — a common precursor for both endothelial cell and hematopoietic cell — was first postulated (Fig. 2). Notably, it was almost 100 years later that the presence of the hemangioblast was confirmed [5]. Differentiation of pluripotent embryonic precursor cells into hemangioblastic cells is induced to at least
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, HIF-1 promotes tumor metastasis into distant and more oxygenated tissues through the transcriptional activation of oncogenic growth factors such as transforming growth factor beta3 (TGF-β3), epidermal growth factor (EGF) and others13, 14.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [13]
In the citing paper
“Another example involves the HIF-1 transcriptional induction of several pro-angiogenic factors such as the vascular endothelial growth factor (VEGF), which in turn stimulates the development of new blood vessels to enrich tumor cells with oxygen for their growth13.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [13]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Mechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Cited by
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
“mediated through stimulation of pro-angiogenic molecule production such as VEGF-R2 (Flk-1), members of the FGF family and PDGF, important in the primitive vascular network formation.(64,66) ii) Hypoxia and HIF-α are also involved in the angiogenesis process by inducing enzymes’ expression (ie, MMPs) in order to sprout…”
BackgroundHIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
“HIF-1α mRNA expression EZN-2698 (1) HIF-1α mRNA Aminoflavone (2) HIF-1α translation CPTs (3): Topoisomerase I topotecan (3a), EZN-2208 (3b), SN38 (3c), irinotecan (3d) Temsirolimus (4) mTOR Everolimus (4a) Sirolimus (4b) LY294002 (5) PI3K Wortmannin (6) Cardiac glycosides (7): HIF-1α protein/HIF-2α mRNA digoxin (7a),…”
BackgroundHypoxia-Inducible Factor-1 (HIF-1)
Ke, Q., & Costa, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027029 · Cited by 1,646
Spiller, K. L., Nassiri, S., Witherel, C. E., Anfang, R. R., Ng, J., Nakazawa, K. R., Yu, T., & Vunjak-Novakovic, G. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.017 · Cited by 773
Metadata
- Authors
- Conway, E.
- Affiliations
- KU Leuven (BE)
- Corresponding author
- Conway, E
- ORCID
- Conway, E
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-02-16
- Volume
- 49
- Issue
- 3
- Pages
- 507-521
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2172253185
- Cited by
- 1,030
- References
- 140
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 27 · 2023: 37 · 2022: 38 · 2021: 48 · 2020: 38 · 2019: 33 · 2018: 23 · 2017: 44 · 2016: 39 · 2015: 41 · 2014: 35 · 2013: 42 · 2012: 43
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiovascular Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- vasculogenesis, angiogenesis, angiogenic factors, anti-angiogenic factors, endothelial cells, angioblasts, pericytes, arteriogenesis, extracellular matrix, vascular remodeling, blood vessel development, gene therapy, knockout mice, angiogenesis inhibitors
- MeSH terms
- Animals, Arteries, Blood Vessels, Cell Differentiation, Cell Division, Endothelium, Vascular, Growth Substances, Morphogenesis, Oxygen, Stress, Mechanical, Veins, Yolk Sac, Signal Transduction, Gene Expression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular mechanisms of blood vessel growth. https://app.cochat.ai/papers/10.1016/s0008-6363(00)00281-9
- The paper
- Conway, E. (2001). Molecular mechanisms of blood vessel growth. Cardiovascular Research. https://doi.org/10.1016/s0008-6363(00)00281-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.